Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free EVLO Stock Alerts

Evelo Biosciences (EVLO) Competitors

Evelo Biosciences logo
$0.0003 0.00 (0.00%)
As of 05/1/2026
Compare

EVLO vs. CARM, SCPS, TRVN, NAVB, and AMPE

Should you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Carisma Therapeutics (CARM), Scopus BioPharma (SCPS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry.

How does Evelo Biosciences compare to Carisma Therapeutics?

Evelo Biosciences (NASDAQ:EVLO) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Carisma Therapeutics has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evelo Biosciences has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Carisma Therapeutics -254.28%N/A -192.17%

In the previous week, Evelo Biosciences had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Carisma Therapeutics. Evelo Biosciences' average media sentiment score of 0.64 beat Carisma Therapeutics' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Evelo Biosciences Positive
Carisma Therapeutics Neutral

Carisma Therapeutics has a consensus target price of $1.00, indicating a potential upside of 199,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Evelo Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evelo Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

Evelo Biosciences has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Carisma Therapeutics beats Evelo Biosciences on 11 of the 15 factors compared between the two stocks.

How does Evelo Biosciences compare to Scopus BioPharma?

Evelo Biosciences (NASDAQ:EVLO) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

In the previous week, Evelo Biosciences had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Scopus BioPharma. Evelo Biosciences' average media sentiment score of 0.64 beat Scopus BioPharma's score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Evelo Biosciences Positive
Scopus BioPharma Neutral

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Scopus BioPharma N/A N/A N/A

0.3% of Evelo Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Evelo Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500.

Summary

Evelo Biosciences beats Scopus BioPharma on 4 of the 6 factors compared between the two stocks.

How does Evelo Biosciences compare to Trevena?

Trevena (NASDAQ:TRVN) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Trevena has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

In the previous week, Evelo Biosciences had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Trevena. Evelo Biosciences' average media sentiment score of 0.64 beat Trevena's score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Trevena Neutral
Evelo Biosciences Positive

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Evelo Biosciences N/A N/A N/A

Trevena has higher revenue and earnings than Evelo Biosciences. Trevena is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

13.6% of Trevena shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Evelo Biosciences beats Trevena on 6 of the 10 factors compared between the two stocks.

How does Evelo Biosciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Evelo Biosciences had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Navidea Biopharmaceuticals. Evelo Biosciences' average media sentiment score of 0.64 beat Navidea Biopharmaceuticals' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Evelo Biosciences Positive

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Evelo Biosciences N/A N/A N/A

Navidea Biopharmaceuticals has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

Summary

Navidea Biopharmaceuticals beats Evelo Biosciences on 5 of the 9 factors compared between the two stocks.

How does Evelo Biosciences compare to Ampio Pharmaceuticals?

Evelo Biosciences (NASDAQ:EVLO) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Evelo Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 7.65, indicating that its stock price is 665% more volatile than the S&P 500.

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Evelo Biosciences had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Ampio Pharmaceuticals. Evelo Biosciences' average media sentiment score of 0.64 beat Ampio Pharmaceuticals' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Evelo Biosciences Positive
Ampio Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Ampio Pharmaceuticals N/A N/A N/A

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

Summary

Evelo Biosciences and Ampio Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

Get Evelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVLO vs. The Competition

Export
MetricEvelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5K$892.30M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio0.001.7229.0328.47
Price / SalesN/A120.12476.1060.92
Price / CashN/A20.0727.6236.52
Price / BookN/A7.609.676.67
Net Income-$114.53M-$4.80M$3.55B$332.53M
7 Day PerformanceN/A0.09%1.75%2.03%
1 Month PerformanceN/A5.64%5.66%9.23%
1 Year PerformanceN/A30.92%34.42%39.62%

Evelo Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVLO
Evelo Biosciences
N/A$0.00
flat		N/AN/A$5KN/AN/A120
CARM
Carisma Therapeutics
2.3313 of 5 stars		$0.00
-16.7%		$1.00
+199,900.0%		N/A$21K$10.77M0.0020
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
TRVN
Trevena
N/A$0.01
flat		N/AN/A$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVLO) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel